ArticleNeoplasia (New York, N.Y.)2006
Angiopoietin-4 inhibits angiogenesis and reduces interstitial fluid pressure.
Article in Neoplasia (New York, N.Y.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02399410 (BEV-IP), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Trial
- Mechanistic studies and therapeutic potential of angiopoietin in head and neck tumor angiogenesis.Frontiers in oncology · 2025Review
- Angiopoietin-4 expression and potential mechanisms in carcinogenesis: Current achievements and perspectives.Clinical and experimental medicine · 2024Review
- Angiopoietin4 (ANGPT4) expression and potential mechanisms in carcinogenesis: current achievements and perspectives.Clinical and experimental medicine · 2023Review
- Combined anticancer therapy with imidazoacridinone analogue C-1305 and paclitaxel in human lung and colon cancer xenografts-Modulation of tumour angiogenesis.Journal of cellular and molecular medicine · 2022Article
- Update Overview of the Role of Angiopoietins in Lung Cancer.Medicina (Kaunas, Lithuania) · 2021Review
- Fibroblast GATA-4 and GATA-6 promote myocardial adaptation to pressure overload by enhancing cardiac angiogenesis.Basic research in cardiology · 2021Article
- Angiopoietin-4 increases permeability of blood vessels and promotes lymphatic dilation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015Article
- Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384.Journal of neurovirology · 2014Article
- Angiogenesis and hypoxia in the kidney.Nature reviews. Nephrology · 2013Review
- A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.British journal of pharmacology · 2012Article
- Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2.PloS one · 2011Article
- Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis.Cancer research · 2010Article
- Targeting the ANGPT-TIE2 pathway in malignancy.Nature reviews. Cancer · 2010Review
- PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention.Genes & cancer · 2010Article
- Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system.Nature reviews. Molecular cell biology · 2009Review
- The angiopoietin/Tie2 axis mediates malignant pleural effusion formation.Neoplasia (New York, N.Y.) · 2009Article
- Sonic hedgehog-responsive genes in the fetal prostate.The Journal of biological chemistry · 2009Article
- Neoplasia: the second decade.Neoplasia (New York, N.Y.) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiopoietins (Ang) are involved in the remodeling, maturation, and stabilization of the vascular network. Ang-4 was discovered more recently; thus, its effect on angiogenesis and its interplay with other angiogenic factors have not been equivocally established. The role of Ang-4 in angiogenesis was tested in Matrigel chambers implanted into the subcutaneous space of nude mice. Ang-4 inhibited the angiogenic response of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and GLC19 tumor cells. In Matrigel chambers with Ang-4-transfected cells, the mean response was significantly lower than that of mock cells. Subcutaneous tumor interstitial fluid pressure (IFP) was significantly lower in Ang-4-transfected GLC19 tumors than in mock-transfected tumors. IFP reduction in Ang-4-transfected tumors was comparable to the reduction seen after bevacizumab treatment. In vitro, we examined the effect of recombinant Ang-4 on endothelial cell migration in Boyden chambers. Human umbilical vein endothelial cell (HUVEC) migration induced by bFGF and VEGF was inhibited by Ang-4 to control levels. In conclusion, we show that rhAng-4, as well as transfection with Ang-4, inhibits angiogenesis induced by GLC19 tumor cells and that Ang-4 expression reduces elevated tumor IFP. In addition, we demonstrate that rhAng-4 inhibits HUVEC migration and growth factor-induced angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.